var data={"title":"Spiramycin (United States: Available via FDA or other investigational drug [IND] protocol only): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Spiramycin (United States: Available via FDA or other investigational drug [IND] protocol only): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6982?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">see &quot;Spiramycin (United States: Available via FDA or other investigational drug [IND] protocol only): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4004351\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Rovamycine&reg;</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222759\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Macrolide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222730\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mild to moderate infections:</b> Oral: 6,000,000 to 9,000,000 units (4 to 6 capsules of Rovamycine &ldquo;500&rdquo; per day) in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe infections:</b> Oral: 12,000,000 to 15,000,000 units (8 to 10 capsules of Rovamycine &ldquo;500&rdquo; per day) in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonorrhea:</b> Oral: 12,000,000 to 13,500,000 units (8 to 9 capsules of Rovamycine &ldquo;500&rdquo;) as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute toxoplasmosis in pregnancy (&lt;18 weeks' gestation) (off-label use):</b> Oral: 1 g (3,000,000 units) every 8 hours to prevent transmission to fetus (Daffos 1988; Hohlfield 1980; Montoya 2008). At &ge;18 weeks, if there is <b>no</b> evidence of transmission to the fetus, spiramycin can be continued until term. <b>Note:</b> If intrauterine fetal <i>Toxoplasma</i> infection is confirmed, treatment should be switched to pyrimethamine plus sulfadiazine and folinic acid (Montoya 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991970\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222743\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">Susceptible infections: Oral: Dosage by body weight; usual dosage 150,000 units/kg; expressed as the number of 750,000 unit (Rovamycine &ldquo;250&rdquo;) capsules per day. Daily dose should be administered in 2 to 3 divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">15 kg = 3 capsules per day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">20 kg = 4 capsules per day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">30 kg = 6 capsules per day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b> Note:</b> In severe infections, dosage may be increased by 50%.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51160247\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222731\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12802304\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rovamycine &ldquo;250&rdquo;: 750,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rovamycine &ldquo;500&rdquo;: 1,500,000 units</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11234333\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50509528\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Spiramycin is not commercially available in the US; it is available for treatment of toxoplasmosis in pregnant women through the Palo Alto Medical Foundation Toxoplasma Serology Lab (650-853-4828), the US National Collaborative Treatment Trial Study (773-834-4152), or the US Food and Drug Administration (301-796-1600).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9614171\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222714\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of infections of the respiratory tract, buccal cavity, skin and soft tissues due to susceptible organisms. <i>N. gonorrhoeae</i>: as an alternate choice of treatment for gonorrhea in patients allergic to the penicillins. Before treatment of gonorrhea, the possibility of concomitant infection due to <i>T. pallidum</i> should be excluded</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744911\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute toxoplasmosis in pregnancy (&lt;18 weeks' gestation)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222706\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactic shock, angioedema, hepatotoxicity (idiosyncratic; Chalasani 2014), paresthesia, pseudomembranous colitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222716\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to spiramycin, other macrolides (eg, erythromycin) or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222704\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Altered cardiac conduction: Macrolides have been associated with rare QT<sub>c</sub> prolongation and ventricular arrhythmias, including torsade de pointes; use with caution in patients at risk of prolonged cardiac repolarization.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with pre-existing liver disease; hepatic impairment, including hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been observed. Discontinue if symptoms of malaise, nausea, vomiting, abdominal colic, and fever.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222753\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222708\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10092&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbidopa: Spiramycin may decrease the serum concentration of Carbidopa. And thus may decrease the effectiveness of levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: Macrolide Antibiotics may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222710\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">Not assigned (other macrolides rated B); C per expert analysis (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222719\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Crosses placenta. Specific safety information is not available. However, spiramycin has been used to treat <i>Toxoplasma gondii</i> to prevent transmission from mother to fetus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222720\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Excreted in breast milk in bacteriostatic concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222721\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Food may improve gastrointestinal tolerance.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222703\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits growth of susceptible organisms; mechanism not established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222722\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acetylspiramycin (JP);</li>\n      <li>Glonacin (VN);</li>\n      <li>Razex (JO);</li>\n      <li>Rovadin (ID);</li>\n      <li>Rovamax (PH);</li>\n      <li>Rovamicina (BR, CO, IT);</li>\n      <li>Rovamitsyn (UA);</li>\n      <li>Rovamycin (AT, BD, EG, IL, KW, NO, TH);</li>\n      <li>Rovamycin Forte (IN);</li>\n      <li>Rovamycine (AE, AR, BE, BG, BH, CH, CR, CZ, DE, DO, EE, ES, FR, GR, GT, HK, HN, HU, ID, JO, KR, LB, LT, LU, LV, MY, NI, NL, PA, PK, PL, PT, PY, QA, RO, RU, SG, SI, SK, SV, VN, ZW);</li>\n      <li>Sipracin (BD);</li>\n      <li>Spiradan (ID);</li>\n      <li>Spiranter (ID);</li>\n      <li>Spirasin (ID);</li>\n      <li>Varoc (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8452648\"></a>Couvreur J, Thulliez P, Daffos F, et al. In utero treatment of toxoplasmic fetopathy with the combination pyrimethamine-sulfadiazine. <i>Fetal Diagn Ther</i>. 1993;8(1):45-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/8452648/pubmed\" target=\"_blank\" id=\"8452648\">8452648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3336419\"></a>Daffos F, Forestier F, Capella-Pavlovsky M, et al. Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. <i>N Engl J Med</i>. 1988;318(5):271-275.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/3336419/pubmed\" target=\"_blank\" id=\"3336419\">3336419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2681638\"></a>Hohlfeld P, Daffos F, Thulliez P, et al. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. <i>J Pediatr</i>. 1989;115(5 Pt 1):765-769.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/2681638/pubmed\" target=\"_blank\" id=\"2681638\">2681638</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2681638\"></a>Montoya JG, Remington JS. Management of <i>Toxoplasma gondii</i> infection during pregnancy. <i>Clin Infect Dis</i>. 2008;47(4):554-566.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/2681638/pubmed\" target=\"_blank\" id=\"2681638\">2681638</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rovamycine (spiramycin) [product monograph]. Quebec, Canada: Aventis Pharma Inc.; October 2000.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10092 Version 109.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F4004351\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F222759\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F222730\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991970\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F222743\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51160247\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F222731\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F12802304\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11234333\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F50509528\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9614171\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F222714\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744911\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F222706\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F222716\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F222704\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F222753\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F222708\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F222710\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F222719\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F222720\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F222721\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F222703\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F222722\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10092|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">Spiramycin (United States: Available via FDA or other investigational drug [IND] protocol only): Patient drug information</a></li></ul></div></div>","javascript":null}